Fully human antibody $V_H$ domains to generate mono and bispecific CAR to target solid tumors

Guanmeng Wang,¹ Xin Zhou,¹ Giovanni Fucà,¹ Elena Dukhovlinova,¹ Peishun Shou,¹ Hongxia Li,¹ Colette Johnston,² Brian Mcguinness,² Gianpietro Dotti,¹,3 Hongwei Du¹

ABSTRACT
Background Chimeric antigen receptor (CAR) T cells are effective in B-cell malignancies. However, heterogeneous antigen expression and antigen loss remain important limitations of targeted immunotherapy in solid tumors. Therefore, targeting multiple tumor-associated antigens simultaneously is expected to improve the outcome of CAR-T cell therapies. Due to the instability of single-chain variable fragments, it remains challenging to develop the simultaneous targeting of multiple antigens using traditional single-chain fragment variable (scFv)-based CARs.

Methods We used Humabody $V_H$ domains derived from a transgenic mouse to obtain fully human prostate-specific membrane antigen (PSMA) $V_H$ and mesothelin (MSLN) $V_H$ sequences and redirect T cell with $V_H$ based-CAR. The antitumor activity and mode of action of PSMA $V_H$ and MSLN $V_H$ were evaluated in vitro and in vivo compared with the traditional scFv-based CARs.

Results Human $V_H$ domain-based CAR targeting PSMA and MSLN are stable and functional both in vitro and in vivo. $V_H$ modules in the bispecific format are capable of binding their specific target with similar affinity as their monovalent counterparts. Bispecific CARs generated by joining two human antibody $V_H$ domains can prevent tumor escape in tumor with heterogeneous antigen expression.

Conclusions Fully human antibody $V_H$ domains can be used to generate functional CAR molecules, and redirected T cells elicit antitumoral responses in solid tumors at least as well as conventional scFv-based CARs. In addition, $V_H$ domains can be used to generate bispecific CAR-T cells to simultaneously target two different antigens expressed by tumor cells, and therefore, achieve better tumor control in solid tumors.

INTRODUCTION
Chimeric antigen receptors (CARs) typically consist of an extracellular antigen-binding domain in the form of a single-chain fragment variable (scFv), a transmembrane domain and signaling molecules such as costimulatory endodomains and CD28 $\zeta$ chain.1 2 Expression of CARs in T cells enables specific targeting of surface antigens in a Major Histocompatibility Complex-independent manner and associated T cell activation.4 5 While classical CARs use scFvs as the antigen-binding moiety, other ligands fused with signaling molecules of the T-cell receptor complex can also trigger phosphorylation events in T cells.6 For example, engineering of natural receptors such as NKG2D and CD27 fused with CD28 $\zeta$ have been shown to redirect T cell specificity.7 8 Ligands to receptors such as interleukin (IL)-13R$\alpha_2$ have also been engineered to redirect T cell specificity towards glioblastoma.9 More recently, synthetic antigen binding moieties as exemplified by a ‘monobody’ based on the type III domain of fibronectin have also been shown to serve as a robust platform to generate CAR molecules.10 Therefore, using alternative binding moieties to replace scFvs to generate CAR remains a critical area because scFvs are frequently unstable and showing intrinsic tendency to self-aggregation, which may lead to tonic signaling and loss of function of CAR-T cells in vivo.11 12

A scFv molecule is composed of paired antibody (Ab) light chain and heavy chain variable domains ($V_L$ and $V_H$) that are fused into a single polypeptide chain via a short flexible linker.11 13 14 Heavy-chain-only Abs without light chains have been reported in camels and cartilaginous fishes,15–17 and shown to exhibit strong and specific antigen binding.13 Single domains targeting BCMA (B-cell maturation antigen) have been developed to generate BCMA-specific CAR-T cells for the treatment of multiple myeloma.18 Whether human-derived $V_H$ only domains can be used as a CAR to target antigens expressed in solid tumors is unknown.

Treatment failure and/or disease recurrence after CAR-T cell therapy can be caused by epitope or antigen loss.19 In particular, the inherently heterogeneous expression pattern of antigens in solid tumors can easily cause tumor escape after targeted
immunotherapy. Therefore, targeting multiple tumor-associated antigens (TAA$s) is generally expected to improve the outcome of CAR-T cell therapy in solid tumor. However, including multiple scFv$s within a CAR causes protein instability and decreases binding specificity and affinity. $V_H$ domain-only format of CAR$s provide an ideal solution for multiple antigen targeting because $V_H$ domains have smaller size and may easily fold correct 3D structure compared to scFv molecules.

Here, we explored the use of Humbody $V_H$ domains derived from a transgenic mouse to develop CAR$s$ that target prostate-specific membrane antigen (PSMA) and mesothelin (MSLN). We found that Humbody-based CAR$s$ exhibited comparable or superior antitumor activity compared with traditional scFv CAR$s$. Moreover, we demonstrated that Humbody$s$ were suitable for constructing bispecific CAR-T cells, which can significantly better control tumors with heterogeneous antigen expression.

**MATERIALS AND METHODS**

**Generation of $V_H$ domains**

Crescendo Mouse was immunized with PSMA and MSLN recombinant proteins. Spleens and lymph nodes were harvested, cloned into a phagemid vector and selected by phage display. Outputs were screened for specific target binding and further characterized.

**CAR construction**

The following antigen-binding moieties were used: scFv derived from the J591 Ab specific for PSMA; human $V_H$ domain-specific for PSMA (PSMA-$V_H$); scFv derived from a MSLN-specific Ab (Amatuximab; human $V_H$ domain-specific for MSLN (MSLN-$V_H$). All ligands were assembled with the CD8α hinge and transmembrane domain, the CD28 costimulatory domain and CD3ζ intracellular signaling domain and cloned into the SFG retroviral vector. A FLAG-tag was incorporated after the antigen ligand to detect the expression of CAR$s$ by an anti-FLAG Ab. Dual-specific (PSMA and MSLN) CAR$s$ were also generated by linking the two $V_H$ domains. The corresponding CAR$s$ were called J591, PSMA-$V_H$, MSLN scFv, MSLN-$V_H$ and PSMA-$V_H$/MSLN-$V_H$. Retroviral supernatants were produced by transfection of 293 T cells with the retroviral vectors, the RD114 envelope from RDF plasmid. Supernatants were collected 48 hours and 72 hours after transfection and filtered with 0.45 µm filter.

**Cell lines**

Tumor cell lines PC-3, C4-2 (prostate cancer) and Aspc-1 (pancreatic cancer) were purchased from ATCC (American Type Culture Collection). All tumor cell lines were cultured with RPMI-1640 (Gibco) supplemented with 10% Fetal bovine serum (Sigma), 2mM GlutaMax (Gibco) and penicillin (100 units/mL) and streptomycin (100 µg/mL; Gibco). All cells were cultured at 37°C with 5% CO₂. PC-3 cell line was transduced with retroviral vectors encoding PSMA or MSLN to make PC-3-PSMA and PC-3-MSLN. PC-3-PSMA, PC-3-MSLN and Aspc-1 were transduced with retroviral vectors encoding Firefly-Luciferase-eGFP (FFLuc-eGFP) gene.

**CAR-T cell generation**

Buffy coats from healthy donors (Gulf Coast Regional Blood Center) were processed with Lymphoprep density separation (Fresenius Kabi Norge) to isolate peripheral blood mononuclear cells, which were then activated on plates coated with 1 µg/mL CD5 (Miltenyi Biotec) and 1 µg/mL CD28 (BD Biosciences) monclonal Abs (mAbs). Two days later, activated T cells were transduced with retroviral supernatants on 24-well plates coated with retronectin (Takara Bio). T cells were collected 3 days after transduction and expanded in 40% RPMI-1640 (Gibco) and 40% Click’s medium (Irvine Scientific), 10% HyClone FBS (GE healthcare), 2mM GlutaMAX (Gibco), 100 unit/mL of Penicillin and 100 mg/mL of streptomycin (Gibco) with 10 ng/mL IL-7 (Peprotech) and 5 ng/mL IL-15 (Peprotech). T cells were collected for functional assays 12-14 days after activation.

**Flow cytometry**

mAbs for human CD3 (APC-H7; SK7; 560176), CD4 (BV711; SK3; 563028), CD8 (APC; SK1; 340584), CD45RA (PE; HI100; 555489), CD45RO (BV786; UCHL1; 564290), CD69 (FITC; L78; 347823), CCR7 (FITC; 150503; FAB197F-100), PD-1 (PE-Cy7; EH12.1; 561272), Lag3 (PE-T45; 565616), FLAG (APC; L5; 63708), Granzyme-B (PE; GB11; 561142) from BD biosciences and BioLegend were used. Samples were acquired with BD FACSCanto II or BD LSRFortessa. A minimum of 10,000 events were acquired for each sample and were analyzed using FlowJo (FlowJo).

**Western blot**

CAR-T cells were incubated with 2 µg anti-FLAG Ab in 100 µL PBS for 20 mins on ice and then with 2 µg goat antimouse secondary Ab for another 20 mins on ice. Cells were then incubated in the 37°C water bath for the selected time points and then lysed with 2 x Laemelli buffer for 10 mins. Cell lysates were then separated in 4% to 15% 10 well SDS-PAGE gels and transferred to polyvinylidene difluoride membranes at 75V for 120 mins (Bio-Rad). Blots were examined for human CD3ζ (Santa Cruz Biotechnology), pY142 CD3ζ (Abcam), pan-ERK (BD Biosciences), and pan-Akt, p-S473 Akt, and p-T202/ Y204 MAPK (Cell Signaling Technology) with 1:1000 dilution in 5% TBS-Tween milk. Membranes were incubated with HRP-conjugated secondary goat anti-mouse or goat anti-rabbit IgG (Santa Cruz) at a dilution of 1:5000 and imaged with the ECL substrate kit (Thermofisher) on the ChemiDoc MP System (Bio-Rad) according to the manufacturer’s instructions.
Proliferation assay

T cells were labeled with 1.5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) and plated with tumor cells at an effector to target (E:T) ratio of 1:1. CFSE signal dilution from gated T cells on day 5 was measured using flow cytometry.26

In vitro cytotoxicity assay

Tumor cells were seeded in 24-well plates at a concentration of 2.5×10^5 cells/well overnight. CAR-T cells were added to the plate at an E:T of 1:5 without exogenous cytokines. Cocultures were analyzed 5–7 days following coculture to measure residual tumor cells and T cells by flow cytometry. Dead cells were recognized by Zombie Aqua Dye (Biolegend) staining while CAR-T cells were identified by CD3 staining and tumor cells by GFP. CD69, PD-1 and Lag3 expression was measured by flow cytometry from day 0 to day 5 each day after coculture of CAR-T cells with tumor cells. For the granzyme-B staining, Golgi protein inhibitor (BD Biosciences) was added on day 1 of coculture for 6 hours. Cocultures were then first stained with Zombie Aqua Dye (Biolegend) and CD3 mAb, followed by fixation/permeabilization solution (BD Biosciences). Intracellular staining of granzyme-B was then conducted.

Cytokine analysis

CAR-T cells (1×10^5 cells) were cocultured with 2.5×10^5 tumor cells in 24-well plates without exogenous cytokines. Supernatant was collected after 24 hours, and cytokines (interferon-γ (IFN-γ) and IL-2) were measured by using ELISA kits (R&D, Research And Development system) in duplicates following manufacturer’s instructions.26

Expression and purification of recombinant proteins

A panel of recombinant proteins was produced, comprising bispecific (2VH) proteins that bind both PSMA and MSLN, monospecific VH protein binding PSMA, monospecific VH protein binding MSLN and a control scFv protein based on Amatuximab. Bispecific protein was made in two formats, one with a short flexible linker (G4S)_5, another one with a long flexible linker (G4S)_6. Bispecific proteins were expressed in mammalian cells and purified by protein A binding. Monospecific proteins were His tagged at the C terminus, expressed in *Escherichia coli* and purified by His trap and size exclusion chromatography.

Binding and kinetic analysis

Binding analyses were performed at 25°C using BIAcore 8K system. The instrument was run on 1x HBS-EP+ (BR100669) buffer and the data were analyzed using Biacore Insight Evaluation software. Recombinant human MSLN was diluted to 2 μg/mL in 10 mM sodium acetate buffer pH 4.0 and immobilized on a CM5 sensor chip (contact time 120s) using amine-coupling kit with accordance to the manufacturer’s instructions. Humabody VH samples were tested for binding at 5 concentrations 3.7 nM, 11.1 nM, 33.3 nM, 100 nM and 300 nM using multicycle kinetics method. Each sample was injected for 100s at the flow rate 35 μL/min and dissociated for 100s. The antigen surface was regenerated by 20s injection of 10 mM glycine pH 2.0. Recombinant human PSMA antigen with a human Fc tag was captured on a Protein G sensor. Humabody VH samples were tested in single-cycle kinetics mode at increasing concentrations of 2.22 nM, 6.67 nM, 20 nM and 60 nM with 90s association and 600s dissociation time at the flow rate of 30 μL/min. Buffer injections were made to allow for double-reference subtraction. The sensor surface was regenerated with 10 mM glycine pH1.5 (GE Healthcare BR100354). To detect dual binding to MSLN and PSMA, human PSMA antigen surface was captured as above. Bispecific PSMA-MSLN Humabody constructs were captured on the PSMA surface by injecting 100 nM of each sample for 100s at 35 μL/min flow rate. The capture was immediately followed by an injection of 300 nM recombinant human MSLN with 100s contact time and 100s dissociation. A PSMA-specific Humabody construct without a MSLN-binding arm was used as a control.

Xenograft murine models

NSG (NOD scid gamma mouse) mice (6–8 weeks old) were injected intravenously through tail vein with either PC-3-PSMA-FFLuc-eGFP, or PC-3-PSMA-FFLuc-eGFP and PC-3-MSLN-FFLuc-eGFP mixed at 1 to 1 ratio, or Asp-c1-FFLuc-eGFP tumor cells of 1×10^6 cells per mice. Fourteen days later, CAR-T cells were injected intravenously through tail vein. For the high dose treatment, 4×10^6 CAR-T cells per mice were injected, while for the low dose treatment, 1×10^6 CAR-T cells per mice were injected. In the rechallenge experiments, mice were infused 1×10^6 tumor cells per mice on clearance of the previous tumor. Tumor growth was monitored by bioluminescence using IVIS (In Vivo Imaging Systems)-Kinetics Optical in vivo imaging system (PerkinElmer) (PSMA-VH and MSLN-VH part) or AMI (AMI Medical Imaging) Optical in vivo imaging system (Spectral instruments imaging) (PSMA-VH/MSLN-VH part).

Statistics

All data was calculated and represented as mean with SD. One-way analysis of variance (ANOVA) or two-way ANOVA analyses were performed to compare multiple groups. Two-tailed t-test was used to compare two groups. P value of less than 0.05 was significant. All calculations and figures were achieved by GraphPad Prism V.7 (La Jolla, California, USA).

RESULTS

Human VH domain-based CAR targeting PSMA is expressed and signals in T cells

We constructed the PSMA-specific CARs using the scFv from the J591 mAb (J591) and the PSMA binding human
V_{H} domain (PSMA-V_{H}) joined to the CD8α stalk, CD28 costimulatory domain and CD3ζ intracellular domain. A flag-based tag was incorporated into the cassettes to detect CAR expression by flow cytometry (figure 1A). Activated T cells were successfully transduced and expressed the CARs equally (figure 1B,C). The CD19-specific CAR (CD19) and non-transduced T cells (NT) were used as positive and negative controls, respectively. **P<0.001, one-way ANOVA. (D) In vitro expansion of CD19, J591, PSMA-V_{H} and NT T cells; error bars represent SD, (n=4). P≥0.05 by one-way ANOVA. (E) T cell subset composition based on CD45RA and CCR7 expression in CD19, J591, PSMA-V_{H} and nt T cells at day 14 of culture; error bars represent SD, (n=4). P≥0.05 by one-way ANOVA. (F) Western blots detecting phosphorylation of CAR-CD3ζ, Akt and ERK in J591 and PSMA-V_{H} T cells activated via CAR cross-linking with an anti-FLAG ab followed by incubation with a secondary ab to induce the aggregation of car molecules. Total CAR, CD3ζ and endogenous CD3ζ were used as loading controls. Data are representative of two experiments. ANOVA, analysis of variance; CAR, chimeric antigen receptor; MSLN, mesothelin; PSMA, prostate-specific membrane antigen.

**Figure 1** Human antibody V_{H} domain-based CAR targeting PSMA is expressed and signals in T cells. (A) Schematic diagram of J591 and PSMA-V_{H} constructs. (B, C) Representative flow cytometry plots (B) and summary (C) illustrating J591 and PSMA-V_{H} expression in T cells. The CD19-specific CAR (CD19) and non-transduced T cells (NT) were used as positive and negative controls, respectively. ****P<0.0001, one-way ANOVA. (D) In vitro expansion of CD19, J591, PSMA-V_{H} and NT T cells; error bars represent SD, (n=4). P≥0.05 by one-way ANOVA. (E) T cell subset composition based on CD45RA and CCR7 expression in CD19, J591, PSMA-V_{H} and nt T cells at day 14 of culture; error bars represent SD, (n=4). P≥0.05 by one-way ANOVA. (F) Western blots detecting phosphorylation of CAR-CD3ζ, Akt and ERK in J591 and PSMA-V_{H} T cells activated via CAR cross-linking with an anti-FLAG ab followed by incubation with a secondary ab to induce the aggregation of car molecules. Total CAR, CD3ζ and endogenous CD3ζ were used as loading controls. Data are representative of two experiments. ANOVA, analysis of variance; CAR, chimeric antigen receptor; MSLN, mesothelin; PSMA, prostate-specific membrane antigen.

V_{H} domain (PSMA-V_{H}) joined to the CD8α stalk, CD28 costimulatory domain and CD3ζ intracellular domain. A flag-based tag was incorporated into the cassettes to detect CAR expression by flow cytometry (figure 1A). Activated T cells were successfully transduced and expressed the CARs equally (figure 1B,C). The CD19-specific CAR (CD19) and non-transduced T cells (NT) were used as controls. On transduction, J591-T cells and PSMA-V_{H}-T cells showed similar expansion in vitro when exposed to IL-15 and IL-7 cytokines, which was similar to CD19-T cells and NT-T cells (figure 1D). Furthermore, no differences were observed in T cell composition as assessed by flow cytometry at day 12–14 of culture (figure 1E). We examined proximal signaling of CAR-T cells before and after CAR cross-linking mediated by an anti-Flag Ab. Phosphorylation of the CAR-associated CD3ζ as well as phosphorylation of Akt and ERK were equal in J591-T cells and PSMA-V_{H}-T cells (figure 1F). Therefore, a V_{H} domain-based CAR is expressed and signals in T cells on cross-linking as observed for scFv-based CAR-T cells.

**PSMA-specific V_{H} domain-based CAR-T cells are functional in vitro and in vivo**

To compare the antitumor effect of PSMA-V_{H}-T cells and J591-T cells in vitro, we engineered the PC3 cells to express PSMA antigen (figure 2A), and we observed that J591-T cells and PSMA-V_{H}-T cells showed comparable granzyme-B expression when cultured with or without tumor cells (figure 2B, C and online supplemental figure S1A). Similarly, both PSMA-V_{H}-T cells and J591-T cells showed equal upregulation and subsequent downregulation of CD69 as a marker of T cell activation (figure 2D). Similar upregulation on antigen stimulation and down regulation after antigen removal were observed for PD-L1 and Lag-3 (online supplemental figure S1B-E). We then cocultured PSMA-V_{H}-T cells and J591-T cells in vitro with tumor cells (either PSMA-positive or PSMA-negative), and...
Figure 2  
T cells expressing the human antibody V_{H} domain-based CAR targeting PSMA are functional in vitro. (A) Representative flow cytometry plots showing the expression of PSMA in C4-2, PC3 and PC3 cells engineered with a retroviral vector to express PSMA. (B, C) Representative flow cytometry plots (B) and summary (C) illustrating Granzyme-B expression of T cells expressing either J591 or PSMA-V_{H}, cocultured overnight with a tumor cell line expressing PSMA (PC3-PSMA-eGFP) at E:T ratio of 1:2; error bars represent SD, (n=4). P≥0.05 by t-test. (D, E) Representative flow cytometry plots (D) and summary (E) illustrating the kinetics of CD69 expression of T cells expressing either J591 or PSMA-V_{H} and cocultured overnight with a tumor cell line expressing PSMA (PC3-PSMA-eGFP) at E:T ratio of 1:2. Data are representative of 4 experiments. ***P<0.001 two-way ANOVA. (F) Representative flow cytometry plots showing coculture of CD19, J591 and PSMA-V_{H} T cells with C4-2-eGFP, PC3-eGFP and PC3-PSMA-eGFP. T cells were cocultured with tumor cells at an E:T ratio of 1:5 for 6 days. At day 6, all cells were collected and analyzed by flow cytometry to quantify tumor cells (GFP) and T cells (CD3), respectively. (G) Summary of coculture of CD19, J591 and PSMA-V_{H} T cells with tumor cells in (F); error bars represent SD, (n=4). ****P<0.0001, two-way ANOVA. (H, I) IFN-γ (H) and IL-2 (I) were detected by ELISA in the coculture supernatant of cocultures of CD19, J591 and PSMA-V_{H} T cells with tumor cells as assessed by CFSE dilution. Data are representative of four experiments. ANOVA, analysis of variance; CAR, chimeric antigen receptor; E:T, effector to target ratio; IFN-γ, interferon-γ; IL-2, interleukin 2; MSLN, mesothelin; PSMA, prostate-specific membrane antigen.
measured the remaining tumor cells after 5 days of coculture. CD19-T cells did not eliminate tumor cells, while PSMA-VH-T cells specifically eliminated PSMA-positive target cells (C4-2 and PC3-PSMA) to the same extent as conventional J591-T cells, and did not demonstrate off-target effect on PSMA-negative cells (PC3) (figure 2F,G). We also measured the secretion of IFNγ and IL-2 after 24 hours of coculture with tumor cells. When the PSMA-VH-T and J591-T cells target PSMA-positive C4-2 and PC3-PSMA cells, both of them secreted high amount of IFNγ and IL-2 compared with control CD19-CAR-T cells (figure 2H,I). Furthermore, PSMA-VH-T cells and J591-T cells proliferated similarly on encounter with tumor cells as shown by CFSE dilution (figure 2J). To investigate the antitumor effects of Humabody VH CAR-T cells in vivo, NSG mice engrafted with PSMA-positive tumor cells labeled with Firefly luciferase were treated with high doses (4×10⁶ cells/mouse) of CAR-T cells (figure 3A). CAR-T cell treatment showed tumor control as measured by tumor bioluminescence without differences in mice treated with PSMA-VH-T cells or J591-T cells (figure 3B,C).

Figure 3  T cells expressing the human antibody VH domain-based CAR targeting PSMA are functional in vivo. (A) Schematic of the metastatic prostate cancer model using PC3-PSMA-FFLuc-eGFP tumor cells in NSG mice and treatment with CD19, J591 and PSMA-VH T cells (n=5 mice per group). (B) Representative images of tumor bioluminescence (BLI) at selected time points post T cell injections. (C) Kinetics of tumor BLI post T cell injections. (D) Schematic of the metastatic prostate cancer model using PC3-PSMA-FFLuc-eGFP tumor cells in NSG mice and treatment with low dose of CD19, J591 and PSMA-VH T cells (n ≥4 mice per group). (E) Representative images of tumor BLI at selected time points post-T cell injections for low dose of T cells. (F) Kinetics of tumor BLI post T cell injections low dose of T cells. (G, H) Percentage of T cells in the gate of live cells (G) and total cell numbers (H) in blood, spleen and bone marrow from PC3-PSMA-bearing mice treated with low doses of CAR-T cells. Mice were euthanized at day 58 after CAR-T cells infusion and T cells were identified as CD45⁵CD3⁴ cells by flow cytometry. J594 group (n=5), PSMA-VH group (n=4). P≥0.05 by t-test. CAR, chimeric antigen receptor; BLI, bioluminescence; PSMA, prostate-specific membrane antigen.
Figure 4  T cells expressing the human antibody \( V_\gamma \) domain-based CAR targeting MSLN demonstrate antitumor activity. (A) Schematic diagram of MSLN-scFv and MSLN-heavy-chain-only (MSLN-\( V_H \)) CAR constructs. (B) Summary of coculture of CD19, MSLN-scFv and MSLN-\( V_H \) T cells with Aspc-1-eGFP (MSLN\(^+\)) and PC3-eGFP (MSLN\(^-\)) tumor cell lines. T cells were cocultured with tumor cells at an E:T ratio of 1:5 for 6 days. At day 6, all cells were collected and analyzed by flow cytometry to quantify tumor cells and T cells, respectively. Error bars represent SD, \((n=4)\). \(****P<0.0001\), two-way ANOVA. (C) IFN-\( \gamma \) (upper panel) and IL-2 (lower panel) detected in the supernatants of the cocultures illustrated in (B) as measured by ELISA; error bars represent SD, \((n=4)\). \(****P<0.0001\), two-way ANOVA. (D) Representative flow cytometry plots showing the proliferation of MSLN.scFv and MSLN-\( V_H \) T cells in response to tumor cells as assessed by CFSE dilution. Data are representative of three experiments. (E) Schematic of the metastatic pancreatic cancer model using Aspc-1-FFluc-eGFP tumor cells in NSG mice. (F, G) Representative tumor BLI (F) and BLI kinetics (G) of Aspc-1-FFluc-eGFP tumor growth at the representative time points post T cell injections. \((n=5\) mice per group). (H) Kaplan-Meier survival curve of mice in (E) \((n=5\) mice per group). Data are representative of two experiments. (I) Frequency of human CD45\(^+\)CD3\(^+\)cells in blood at 22 days (left) post-T cell infusion and at euthanasia (right) of MSLN-scFv and MSLN-\( V_H \) T cells, respectively. Data are shown as individual values and the mean (\(n=5\) mice per group). \(P\geq0.05\) by t-test. ANOVA, analysis of variance; BLI, bioluminescence; CAR, chimeric antigen receptor; CFSE, carboxyfluorescein diacetate succinimidyl ester; E:T, effector to target ratio; IFN-\( \gamma \), interferon-\( \gamma \); IL-2, interleukin 2; i.v, intravenous; MSLN, mesothelin; scFv, single-chain fragment variable.
Open access

To further assess differences between PSMA-VH-T cells and J591-T cells, we used low doses of T cells (1×10⁶ cells/mouse) in tumor-bearing mice (figure 3D). We observed that PSMA-VH-T cells still eliminated tumor cells in vivo as J591-T cells (figure 3E,F). In addition, we also observed similar VH CAR-T cell persistence in the peripheral blood, spleen and bone marrow compared with traditional scFv-based CAR-T cells at day 58 at the time of euthanasia (figure 3G,H). Therefore, Humabody VH CAR-T cells demonstrated comparable antitumor effects to scFv-based CAR-T cells in vitro and in vivo.

MSLN-specific VH domain-based CAR-T cells demonstrate antitumor activity

To further assess the reproducibility of VH domain-based CARs, we tested a MSLN-specific Humabody VH. We constructed the conventional MSLN scFv CAR (MSLN-scFv) and VH domain CAR (MSLN-VH) using the same backbone developed for PSMA-specific CARs (figure 4A). MSLN-scFv and MSLN-VH were equally expressed in T cells (online supplemental figure S2A, B). In a similar fashion, we examined the antitumor activity of MSLN-scFv-T cells and MSLN-VH-T cells in vitro through coculture experiments with tumor cells, cytokine release assay, proliferation assay. MSLN-scFv-T cells and MSLN-VH-T cells selectively eliminated Aspc-1 tumor cells that express MSLN, while spared PC3 cells that do not express MSLN (figure 4B and online supplemental figure S3). They released similar amount of IFNγ and IL-2 (figure 4C) and proliferated on encounter with tumor cells (figure 4D).

In vitro analysis of monovalent and bivalent VH domain recombinant proteins

To test whether the VH domains are suitable to construct bispecific CARs, two VH domains in tandem recombinant proteins linking PSMA-specific and MSLN-specific VH were generated (figure 5A). To test whether the linkers had any effect on the target binding affinity, two different linkers were used: the (G4S)₃ linker (‘short flexible linker’) and a longer linker (G4S)₆ with 6 copies of the (G4S) repeat (‘long flexible linker’). Monomer VH proteins and a MSLN binding scFv were made as controls (figure 5A). Analysis of binding to PSMA recombinant protein by surface plasmon resonance (SPR) Biacore assay showed that the affinity of the PSMA-VH remained the same when the PSMA-VH was formatted with the MSLN-VH domain...
using either flexible linkers (figure 5B). Similarly, analysis of binding to MSLN recombinant protein by SPR Biacore assay showed that the affinity of the MSLN-V_{H} domain was not altered when the PSMA-V_{H} was formatted with the MSLN-V_{H} using either flexible linkers (figure 5C). In summary, these data show that V_{H} modules in bispecific format are capable of binding their specific target with the same affinity as their monovalent counterparts.

**Bispecific V_{H} domain-based CAR-T cells demonstrate dual specificity**

We constructed a bispecific V_{H} domain CAR to facilitate CAR-T cells to specifically recognize two antigens simultaneously. We used the MSLN-V_{H} and PSMA-V_{H} domains fused with the short (G4S)_{4} linker to generate the bispecific PSMA-V_{H}/MSLN-V_{H} CAR (figure 6A). The PSMA-V_{H}/MSLN-V_{H} CAR was expressed in T cells (figure 6B,C). PSMA-V_{H} T cells, MSLN-V_{H} T cells and PSMA-V_{H}/MSLN-V_{H} T cells were cocultured with tumor the cell line Aspc-1, which express MSLN, and the PC3-PSMA cell line. We
observed the PSMA-VH/MSLN-VH-T can eliminate both tumor cell lines compared with single CAR-T cells, which only eliminate tumor cells expressing the targeted antigen (online supplemental figure S4A, B). In addition, we also observed the expected cytokine release profile (online supplemental figure S4C, D). Next, we confirmed that PSMA-VH/MSLN-VH-T cells displayed specific cytotoxicity toward the same cell line PC3 expressing either MSLN or PSMA similar to MSLN-VH-T cells and PSMA-VH-T cells without off-target effect (figure 6D, E). Importantly, when PC3-PSMA and PC3-MSLN were plated as 1:1 ratio mixture in coculture experiments, only PSMA-VH/MSLN-VH-T cells fully eliminated the tumor cells, although PSMA-VH-T cells and MSLN-VH-T cells showed some bystander killing effect as previously observed27 (figure 6D, E). The in vitro antitumor effect was corroborated by release of IFN-γ and IL-2 (figure 6F, G). To evaluate if bispecific VH domain CAR-T cells can eradicate tumors with mixed antigen expression in vivo, we established a metastatic xenograft mouse model by infusing PC3-PSMA cells and PC3-MSLN cells at 1:1 ratio into NSG mice by intravenous injection. Mice were then treated with CAR19-T, PSMA-VH-T, MSLN-VH-T and PSMA-VH/MSLN-VH-T cells (figure 7A). Dual targeting PSMA-VH/MSLN-VH-T cells controlled the tumor growth more effectively than either single targeting PSMA-VH-T or MSLN-VH-T cells (figure 7B, C). CAR-T cells were detectable in the peripheral blood of these mice up to 4 weeks after infusion (figure 7D). We also observed that T cells expressing bispecific CAR showed similar phenotypic profile as single CAR targeting T cells for exhaustion and memory markers (online supplemental figure S5A-C). Analyses of antigen expression in tumor cells in vivo showed that tumor cells growing in mice receiving either PSMA-VH-T or MSLN-VH-T cells were predominantly MSLN and PSMA expressing cells, respectively (figure 7E). These results indicate that bispecific CARs generated by joining two human Ab VH domains can prevent tumor escape in tumor with heterogeneous antigen expression.
DISCUSSION

CARs approved by the Food and Drug Administration and those in clinical studies are mostly based on scFv-binding moieties. Here we demonstrated that monospecific human V₄ domains-based CAR-T cells achieved comparable antitumor effects both in vitro and in vivo as scFv-based CAR-T cells. Furthermore, V₄ domains combined in tandem to create bispecific molecules allowed the generation of effective CAR-T cells targeting two antigens.

Redirected T cell based on single-domain Abs have been recently proposed. However, most of them are obtained from llamas or camelderived libraries. Biological therapeutic molecules with non-human sequence can cause immune responses. Transgenic mouse technology has enabled the generation of biophysically robust fully human V₄ domains known as Humabody V₄ or Humabodies which have the potential for use in CAR constructs while mitigating immunogenicity risk.

Despite the remarkable clinical activity of CAR-T cells in hematological malignancies, objective responses in patients with solid tumors are modest. Heterogeneity of antigen expression is one of the main reasons causing tumor escape in solid tumors after targeted therapies. Furthermore, murine-based scFv may cause immune responses especially in solid tumor patients who are usually less immunosuppressed compared with patients with liquid tumors. Targeting multiple TAAs and using human binding moieties in CAR molecules may improve the outcome of CAR-T cells in solid tumors.

Here, we demonstrated that human V₄ domains generated from a transgenic mouse might solve both issues of immunogenicity and tumor heterogeneity since bispecific CAR-T cells can be efficiently generated using two human V₄ domains in tandem.

In addition to the issue of heterogeneity in antigen expression, the complex inhibitory pathways of the tumor microenvironment in solid tumors mean that additional genetic modification of T cells would likely be required to enhance T cell trafficking and functions. Generation of vector cassettes encoding multiple genes requires a significant optimization of the engineering strategies since the size of the entire cassette is limited. V₄ domains are a good alternative to scFv since they are approximately half the size.

Here, we have used two target antigens, PSMA and MSLN, that are currently under evaluation to treat mesothelioma, lung cancer, breast cancer, pancreatic cancer and prostate cancer via scFv-based CAR-T cells. Our preclinical experiments validate the potential use of bispecific human V₄ domains targeting both PSMA and MSLN in these difficult to treat malignancies. It remains to be validated if dual or multiple targeting with V₄ domain-based CARs can be broadly applicable, and if targeting multiple antigens in solid tumors leads to increased potential for toxicity.

Additionally, we observed that V₄ domain-based CAR-T cells have comparable cytotoxicity and proliferative capacity as traditional scFv-based CAR-T cells. MSLN-V₄-T cells showed even more profound antitumor effects as compared with mice treated with MSLN-scFv CAR-T cells. Interestingly, MSLN-V₄ showed lower affinity than MSLN-scFv (28 nM compared with 79 pM) recapitulating what has been observed for other scFvs that very high affinity is not necessarily optimal for CAR-based targeting for some targets. However, we cannot exclude that the observed superior antitumor activity of the MSLN-V₄-based CAR-T cells can be associated with the recognition of a different epitope rather than to different affinity. In summary, we have demonstrated that V₄ domain CAR-T cells in monospecific format achieved comparable antitumor response compared with traditional scFv-based CAR-T cells both in vitro and in vivo. Furthermore, bispecific V₄ domain CAR-T cells delivered potent anti-tumor effects demonstrating the potential to target solid tumors with heterogeneous antigen expression. These proof-of-concept experiments lay the foundation for further development of human V₄ domain-based CAR-T cells in clinical trials.

Contributors HD and GD designed the experiments. GW, XZ, HD, GF, ED, PS and HL performed experiments; GW, XZ, HD and GD analyzed data and created the figures. CJ and BM generated the VH Humabody and performed binding and kinetic analysis. GW, XZ, HD and GD wrote the manuscript, all authors reviewed the manuscript.

Funding This work was supported in part by the University Cancer Research Fund at the University of North Carolina at Chapel Hill (GD), R01-CA193140-03 from the National Cancer Institute (GD). HD was supported by W81XWH-18-1-0441 from the Department of Defense (USA) and the Vicky Amidon Innovation Grant in Lung Cancer Research from the Lung Cancer Initiative of North Carolina (USA). The UNC Small Animal Imaging Facility at the Biomedical Imaging Research Center, and the Flow Cytometry Core Facilities are supported in part by an NCI Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center (P30-CA16086-40) USA.

Competing interests GD has sponsored research agreements with Bluebird Bio, Cell Medica, and Bellicum Pharmaceutical. GD serves on the scientific advisory board of MolMed and Bellicum Pharmaceutical. CJ and BM are employees of Crescendo Biologics Ltd.

Patient consent for publication Not required.

Ethics approval The present studies in mice were approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill, North Carolina, USA.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Wang G, et al. J Immunother Cancer 2021;9:e002173. doi:10.1136/jitc-2020-002173 11
REFERENCES

1. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A* 1993;90:720–4.

2. Finney HM, Lawson AD, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. *J Immunol* 1998;161:2791–7.

3. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB-induced costimulation confer potent cytoxicity against acute lymphoblastic leukemia. *Leukemia* 2004;18:676–84.

4. Sadelaïn M, Brentjens R, Rivièrè I. The basic principles of chimeric antigen receptor design. *Cancer Discov* 2013;3:388–98.

5. Dotti G, Gottschalk S, Savolbo B, et al. Design and development of therapies using chimeric single chains expressing anti-HER2 receptor-expressing T cells. *Immunol Rev* 2014;257:107–26.

6. Xiong W, Chen Y, Kang X, et al. Immunological synapse predicts effectiveness of chimeric antigen receptor cells. *Mol Ther* 2018;26:963–71.

7. Barber A, Zhang T, DeMars LR, et al. Chimeric NK2GD receptor-bearing T cells as immunotherapy for ovarian cancer. *Cancer Res* 2007;67:5003–8.

8. Shaffer DR, Savolbo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood* 2011;117:4304–14.

9. Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. *N Engl J Med* 2016;375:2561–9.

10. Ahn S, Li J, Sun C, et al. Cancer immunotherapy with T cells carrying bispecific receptors that mimic antibodies. *Cancer Immunol Res* 2019;7:773–83.

11. Miller BR, Demarest SJ, Lugovskoy A, et al. Stability engineering of scFv for the development of bispecific and multivalent antibodies. *Protein Eng Des Sel* 2010;23:549–57.

12. Landoni E, Fucá G, Wang J, et al. Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling. *Cancer Immunol Res* 2021. doi:10.1158/2326-0606.CIR-20-0451. [Epub ahead of print: 05 Feb 2021].

13. Holliger P, Hudson P.J. Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 2005;23:1126–36.

14. Ahmad ZA, Yeap SK, Ali AM, et al. scFv antibody: principles and clinical application. *Clin Dev Immunol* 2012;2012:1–15.

15. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. *Nature* 1993;363:446–8.

16. Stanfield RL, Dooley H, Flajnik MF, et al. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. *Science* 2003;305:1770–3.

17. Jannanni FR, Rahbarizadeh F, Shokrgozar MA, et al. T cells expressing VH-HD-directed oligoglobal chimeric HER2 antigen receptors: towards tumor-directed oligoglobal T cell therapy. *Biochim Biophys Acta* 2014;1840:378–86.

18. Lamb N, Trinklein ND, Buelow B, et al. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. *Nat Commun* 2020;11:283.

19. O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRVIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci Transl Med* 2017;9(390):eaag0994.

20. Sampson JH, Gunn MD, Fecci PE, et al. Brain immunology and immunotherapy in brain tumours. *Nat Rev Cancer* 2020;20:12–25.

21. Chang SS. Overview of prostate-specific membrane antigen. *Rev Urol* 2004;6 Suppl 10:513–8.

22. Yu H, Pan J, Guo Z, et al. Cart cell therapy for prostate cancer: status and promise. *Onco Targets Ther* 2019;12:391–5.

23. Morello A, Sadelaïn M, Adusumilli PS. Mesothelin-Targeted cars: driving T cells to solid tumors. *Cancer Discov* 2016;6:133–6.

24. Hong LK, Chen Y, Smith CC, et al. CD30 Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen Dependent and Fas/FasL Interactions. *Cancer Immunol Res* 2018;6:1274–87.

25. Wang Q, Chen Y, Park J, et al. Design and production of bispecific antibodies. *Antibodies* 2019;8:43.

26. Du H, Hirabayashi K, Ahn S, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. *Cancer Cell* 2019;35:221–37.

27. Diaconu I, Ballard B, Zhang M, et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. *Mol Ther* 2017;25:580–92.

28. Rajabzadeh A, Rahbarizadeh F, Ahmadvand D, et al. A VHH-Based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells. *Cell J* 2021;22:502–13.

29. Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, et al. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific cameldi single domain antibodies as targeting agents. *Cancer Lett* 2013;334:237–44.

30. Teng Y, Young JL, Edwards B, et al. Diverse human V, antibody fragments with bio-therapeutic properties from the Crescendo Mouse, *N Biotechnol* 2020;50:63–76.

31. Fucá G, Reppel L, Landoni E, et al. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. *Clin Cancer Res* 2020;26:2444–51.

32. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. *Nat Rev Clin Oncol* 2019;16:372–86.

33. Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. *J Clin Oncol* 2020;38:3794–804.

34. Ma X, Shou P, Smith C, et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. *Nat Biotechnol* 2020;38:448–59.

35. Bolland CM, Tripic T, Cruz CR, et al. Tumor-Specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma. *J Clin Oncol* 2018;36:1128–39.

36. Hecezy A, Louis CU, Savolbo B, et al. CAR T cells administered in combination with Lymphodepletion and PD-1 inhibition to patients with neuroblastoma. *Mol Ther* 2017;25:2214–24.

37. Wang D, Shao Y, Zhang X, et al. II-33 and PSMA-targeted duo-CAR T cells in prostate cancer eradication in a preclinical model. *J Transl Med* 2020;18:23.

38. Lv J, Zhao R, Wu D, et al. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. *J Hematol Oncol* 2019;12:19.

39. Zhang Z, Jiang D, Yang H, et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. *Cell Death Dis* 2019;10:476.

40. Watanabe K, Terakura S, Uchiyama S, et al. Excessively high-affinity single-chain fragment variable region in a chimeric antigen receptor can counteract T-cell proliferation. *Blood* 2014;124:4799.

41. Richman SA, Nunez-Cruz S, Moghimi B, et al. High-Affinity GD2-Specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. *Cancer Immunol Res* 2018;6:36–46.

42. Park S, Shvelin E, Vedvyas Y, et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. *Sci Rep* 2017;7:14366.